Alcohol

Concurrent ingestion of acitretin and ethanol can result in formation of etretinate.

Do not mix ALBUMIN HUMAN with alcoholic solutions.

CNS depressant; concomitant use increases risk of hypotension, respiratory depression, profound sedation, coma, and death.

Disulfiram-like reaction with abdominal cramps, nausea, vomiting, headaches, and flushing; do not consume during therapy and for at least 3 days afterwards.

XYWAV is contraindicated for use in combination with alcohol due to potentiation of CNS-depressant effects.

CNS depressant that increases risk of hypotension, respiratory depression, profound sedation, coma, and death when combined with fentanyl.

CNS depressant that increases risk of respiratory depression, profound sedation, coma, and death when combined with fentanyl.

CNS depressant; concomitant use can increase risk of hypotension, respiratory depression, profound sedation, coma, and death.

CNS depressant that increases risk of hypotension, respiratory depression, profound sedation, coma, and death. Concomitant use should be reserved for patients with inadequate alternatives.

Concomitant use increases risk of hypotension, respiratory depression, profound sedation, coma, and death due to additive CNS depressant effects.

Can result in increased hydrocodone plasma levels and potentially fatal overdose. Patients should not consume alcoholic beverages or use products containing alcohol.

Concomitant use can result in increased hydrocodone plasma levels and potentially fatal overdose. Patients should not consume alcoholic beverages.

Can result in increase of hydrocodone plasma levels and potentially fatal overdose of hydrocodone.

Concomitant use may result in profound sedation, respiratory depression, coma, or death.

CNS depressant with increased risk of CNS depression. Avoid concomitant use.

CNS depressant; increased risk of CNS depression. Avoid concomitant use.

Disulfiram-like reaction (abdominal cramps, nausea, vomiting, headaches, and flushing) occurs with concurrent use. Metronidazole is contraindicated during and for at least 3 days after therapy.

Concomitant use may increase incidence and severity of undesirable effects. LAMPIT is contraindicated in patients who consume alcohol during treatment.

CNS depressant that when combined with oxycodone increases risk of hypotension, respiratory depression, profound sedation, coma, and death.

CNS depressant that increases risk of hypotension, respiratory depression, profound sedation, coma, and death when combined with oxycodone and acetaminophen.

CNS depressant that increases risk of hypotension, respiratory depression, profound sedation, coma, and death when combined with oxycodone.

CNS depressant increasing risk of hypotension, respiratory depression, profound sedation, coma, and death when used concomitantly.

CNS depressant that increases risk of respiratory depression, profound sedation, coma, and death due to additive pharmacologic effects.

Causes additive psychomotor impairment. Should not be used in combination with ramelteon.

Sodium oxybate oral solution is contraindicated for use in combination with alcohol due to potentiation of CNS-depressant effects.

Alcohol use is contraindicated within 6 hours prior to and 6 hours after TROKENDI XR administration due to CNS depression risk.

Produces additive CNS depressant effects when co-administered with alprazolam.

Produces additive CNS depressant effects when coadministered with alprazolam.

CNS depressant; refer to WARNINGS section for detailed guidance.

Concomitant administration of high or low dose ethanol with apomorphine hydrochloride causes greater decreases in blood pressure compared to apomorphine alone.

Additive CNS depressant effects increasing risk of hypotension, respiratory depression, profound sedation, coma, and death.

Central nervous system depressant; concurrent use should be avoided due to risk of somnolence and impairment of CNS performance.

CNS depressant effects increase risk of respiratory depression, profound sedation, coma, and death.

Concomitant use increases risk of respiratory depression, profound sedation, coma, and death due to additive CNS depressant effects.

Concomitant use increases risk of respiratory depression, profound sedation, coma, and death due to additive CNS depressant effects.

Concomitant use increases risk of respiratory depression, profound sedation, coma, and death due to additive CNS depressant effects.

Additive CNS depressant effects increase risk of respiratory depression, profound sedation, coma, and death.

Alcohol may enhance effects causing increased CNS depression.

Butalbital causes increased CNS depression when combined with alcohol.

Additive CNS depressant effects increase risk of hypotension, respiratory depression, profound sedation, coma, and death.

Alcohol causes additive CNS depressant effects with carbinoxamine. Avoid concomitant use.

Increases clobazam maximum plasma exposure by approximately 50% and increases risk of sedation and somnolence when used concomitantly.

CNS-depressant action of clonazepam may be potentiated by alcohol, increasing risk of sedation and respiratory depression.

Clonidine may potentiate CNS-depressive effects. Avoid concomitant use.

Clorazepate dipotassium prolongs sleeping time after ethyl alcohol.

Cyclobenzaprine may enhance the effects of alcohol and other CNS depressants.

Alcohol consumption may increase the rate of cysteamine release and adversely alter pharmacokinetic properties, effectiveness, and safety. Do not consume alcoholic beverages during treatment.

Concomitant use of alcohol with daridorexant may lead to additive impairment of psychomotor performance and CNS depression. Alcohol consumption should be avoided.

Concomitant use not recommended due to enhancement of sedative effect.

Concomitant use with alcohol should be avoided due to risk of additive CNS depression and other adverse effects.

Concurrent use not recommended; severe drowsiness can occur when combined with alcohol or other sedating medications.

Severe drowsiness can occur when used in combination with alcohol. Concurrent use is not recommended.

Potentiates benzodiazepine action and increases CNS depression risk.

Additive effect on psychomotor performance when coadministered with eszopiclone.

Coadministration increases risk of hypotension, syncope, and CNS depression compared to ADDYI alone or alcohol alone.

Fomepizole reduces ethanol elimination by approximately 40% via alcohol dehydrogenase inhibition; ethanol reciprocally reduces fomepizole elimination by approximately 50%.

Nausea, vomiting, flushing, tachycardia, and severe hypotension have been reported following alcohol ingestion during griseofulvin therapy.

Additive CNS depressant effects can increase risk of hypotension, respiratory depression, profound sedation, coma, and death.

Increases lemborexant Cmax and AUC with greater negative impact on postural stability and memory when assessed near peak concentration. Alcohol consumption should be avoided with DAYVIGO.

CNS depressant with additive effects increasing risk of hypotension, respiratory depression, profound sedation, coma, and death.

Produces increased CNS-depressant effects including respiratory depression and sedation.

Alcohol may potentiate the action of Mecamylamine HCl.

Potentiates metformin's effect on lactate metabolism, increasing risk of lactic acidosis.

Concomitant use increases risk of respiratory depression, profound sedation, coma, and death due to additive CNS depressant effects.

CNS depressant that increases risk of hypoventilation, airway obstruction, desaturation, apnea, and prolonged drug effect.

Concomitant use accentuates sedative effect of midazolam through CNS depression.

Concomitant use can increase morphine plasma levels and potentially cause fatal overdose. Additive CNS depression increases risk of respiratory depression, coma, and death.

Concomitant use increases risk of respiratory depression, profound sedation, coma, and death due to additive CNS depressant effects.

Concomitant use may cause hypotension.

Concomitant use can increase oxymorphone plasma levels and result in potentially fatal overdose.

Concomitant use increases risk of hypotension, respiratory depression, profound sedation, coma, and death due to additive CNS depressant effects.

Concomitant use may produce additive CNS depressant effects.

Concomitant use increases CNS depression with additive or supra-additive effects on impairment. Enhances alcohol's effects on vigilance, alertness, and increases anger, confusion, and depression.

Additive depressant effects with phenobarbital; toxic effects and fatalities have occurred with this combination.

Concomitant use of alcohol with phenobarbital may produce additive central nervous system depressant effects.

Promethazine may increase, prolong, or intensify sedative action of alcohol.

Potentiates cognitive and motor effects of quetiapine. Alcoholic beverages should be limited while taking quetiapine.

Alcohol potentiates cognitive and motor effects of quetiapine. Alcoholic beverages should be limited while taking quetiapine.

Alcohol causes rapid release of ranolazine from extended-release formulation, increasing risk of adverse events. Patients should not consume alcohol.

CNS depressant that increases risk of hypotension, respiratory depression, profound sedation, coma, and death when combined with remifentanil.

Concurrent use may potentiate CNS adverse reactions including drowsiness, dizziness, and disorientation.

Concurrent use may potentiate CNS adverse reactions including drowsiness, dizziness, or disorientation. Either scopolamine or the interacting drug should be chosen depending on importance.

Potentiates metformin's effect on lactate metabolism, increasing lactic acidosis risk.

CNS depressant that increases risk of hypotension, respiratory depression, profound sedation, coma, and death when combined with sufentanil.

May increase the rate of tacrolimus release and increase risk of serious adverse reactions including neurotoxicity and QT prolongation.

May increase rate of tacrolimus release and increase risk of serious adverse reactions including neurotoxicity and QT prolongation.

Substantial consumption (5+ units) with tadalafil increases potential for orthostatic signs and symptoms including increased heart rate, decreased standing blood pressure, dizziness, and headache.

CNS depressant effect increases risk of respiratory depression, profound sedation, coma, and death.

Produces additive CNS-depressant effects when co-administered with temazepam.

Increases drug levels in bloodstream and increases adverse reactions. CNS depressant effects are additive.

Alcohol increases tizanidine bloodstream concentration and adverse reactions; CNS depressant effects are additive.

Alcohol increases overall amount of tizanidine in bloodstream and CNS depressant effects are additive, resulting in increased adverse reactions.

Additive adverse effect on psychomotor performance and increased risk of CNS depression, drowsiness, and impaired driving ability.

Additive adverse effect on psychomotor performance demonstrated. Possible adverse additive CNS depressant effects.

Ethanol has complex effects on acetaminophen metabolism; excessive alcohol can induce hepatic cytochromes increasing hepatotoxic potential, while also acting as competitive inhibitor of acetaminophen metabolism.

May enhance CNS depressant effects, causing increased CNS depression.

Additive CNS depressant effects with dihydrocodeine; chronic/excessive consumption increases hepatotoxic risk of acetaminophen.

Association with alcoholic beverages has resulted in rash development.

Can potentiate the effect of metformin on lactate metabolism, increasing lactic acidosis risk. Patients should avoid excessive alcohol intake.

Concomitant use may increase CNS effects (dizziness, confusion, lightheadedness, orthostatic hypotension) and result in dose-dumping. Use not recommended.

Potentiation of orthostatic hypotension may occur when given concurrently with hydrochlorothiazide.

Amoxapine may enhance the response to alcohol.

Possibility of additive or potentiating effect with CNS depressants.

Centrally-acting substance; caution advised when combined with aripiprazole due to CNS effects.

Substantial alcohol consumption (>3 units) with avanafil increases orthostatic signs and symptoms including increased heart rate, decreased standing blood pressure, dizziness, and headache.

Concurrent use with azelastine may cause reductions in alertness and impairment of central nervous system performance; concurrent use should be avoided.

Concurrent use may cause reductions in alertness and impairment of central nervous system performance; should be avoided.

Additive CNS depression including drowsiness and sedation when used concomitantly with baclofen oral suspension.

Possibility of additive or potentiating CNS depressant effect with brimonidine.

CNS depressant with potential for additive or potentiating effect when used with brimonidine tartrate ophthalmic solution.

CNS depressant with possibility of additive or potentiating effect on central nervous system depression.

CNS depressant; may result in additive or potentiating effect with brimonidine on the central nervous system.

Potential additive or potentiating effect with CNS depressants. Specific interaction studies not conducted.

Alcohol may potentiate the side effects of bromocriptine mesylate.

Antihistamine component has additive CNS depressant effects with alcohol.

Antihistamines have additive effects with alcohol, which are CNS depressants.

Antihistamines have additive CNS depressant effects with alcohol.

Alcohol may enhance the effects of butalbital and acetaminophen, causing increased CNS depression.

Alcohol may enhance the CNS effects of butalbital and acetaminophen, causing increased CNS depression.

Alcohol may enhance CNS depressant effects of the combination.

Potentiates metformin's effect on lactate metabolism. Warn patients against excessive alcohol intake while receiving INVOKAMET.

Potentiation of orthostatic hypotension may occur with hydrochlorothiazide component.

Alcohol may result in additive or potentiating CNS depressant effects with YUVEZZI.

Additive sedative effects with carisoprodol. Caution should be exercised when used concomitantly.

Potentiation of orthostatic hypotension may occur when alcohol is given concurrently with chlorothiazide.

Potentiation of orthostatic hypotension may occur when alcohol is given concurrently with chlorothiazide sodium.

Use of alcohol by depressed patients taking citalopram is not recommended despite lack of potentiation in cognitive and motor effects in clinical trials.

Use not recommended in depressed patients taking citalopram, consistent with other psychotropic medications, despite lack of potentiation in clinical trials.

Additive CNS depression may occur when antihistamines are administered concomitantly with alcohol.

Clonidine may potentiate the CNS-depressive effects of alcohol.

Clonidine may potentiate CNS-depressive effects of alcohol.

Cyclobenzaprine may enhance the effects of alcohol and CNS depression.

Cyclobenzaprine may enhance the effects of alcohol.

Alcohol may have additive effects with cyproheptadine on CNS depression.

Potentiates metformin's effect on lactate metabolism. Warn patients against excessive alcohol intake.

Patients should be warned that response to alcoholic beverages may be exaggerated while taking desipramine.

Concomitant use may have additive effects and worsen sedation and somnolence.

MOTOFEN may potentiate the action of alcohol; patient should be closely monitored.

Additive CNS depressant effects with diphenhydramine hydrochloride.

Alcohol may increase CNS depressant effects and cause drowsiness. Concomitant use should be avoided.

Sedative effects of alcohol may be potentiated when taken with doxepin.

Alcohol potentiates metformin's effect on lactate metabolism, increasing lactic acidosis risk.

Alcohol potentiates metformin's effect on lactate metabolism, increasing lactic acidosis risk.

Potentiates metformin's effect on lactate metabolism; excessive intake should be avoided.

Potentiates the effect of metformin on lactate metabolism, increasing lactic acidosis risk.

Use of alcohol by patients taking escitalopram is not recommended, although escitalopram did not potentiate cognitive and motor effects in clinical trials.

Use is not recommended with escitalopram despite lack of potentiation in clinical trials, consistent with other psychotropic medications.

Concomitant use may increase sedation. Closely monitor for sedation with concomitant use.

Produces additive CNS depressant effects. Downward dose adjustment of flurazepam and/or ethanol may be necessary.

May increase phenytoin serum levels; monitoring of phenytoin levels recommended.

Alcohol increases the release rate of gabapentin enacarbil from HORIZANT Extended-Release tablets. Consumption of alcohol is not recommended when taking HORIZANT.

CNS depressant that may increase risk of somnolence and sedation when used concomitantly with ganaxolone.

Both acute and chronic alcohol intake may potentiate or weaken the glucose-lowering action of glimepiride in an unpredictable fashion.

May lead to either potentiation or weakening of glucose-lowering effect; increased monitoring required.

Potentiates the effect of metformin on lactate metabolism, increasing lactic acidosis risk.

Potentiates metformin's effect on lactate metabolism.

CNS depressant that may be potentiated by haloperidol decanoate; monitor for combined CNS depression effects.

CNS depressant that haloperidol may potentiate, increasing risk of enhanced CNS depression.

Potentiation of orthostatic hypotension may occur.

May increase or decrease the blood glucose lowering effect. Dose adjustment and increased glucose monitoring required.

May increase or decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.

May increase or decrease blood glucose lowering effect. Dosage adjustment and increased glucose monitoring may be required.

May increase or decrease blood glucose-lowering effect; dosage adjustment and increased glucose monitoring may be required.

May increase or decrease blood glucose lowering effect. Dosage adjustment and increased glucose monitoring may be required.

May increase or decrease blood glucose lowering effect; dosage adjustment and increased glucose monitoring may be required.

May increase or decrease the blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.

May increase or decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.

May increase or decrease blood glucose lowering effect. Dosage adjustment and increased glucose monitoring may be required.

May increase or decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.

May increase or decrease blood glucose lowering effect; dose adjustment and glucose monitoring may be required.

May increase or decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.

May increase or decrease blood glucose lowering effect; dose adjustment and increased glucose monitoring required.

May increase or decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.

Potentiation of orthostatic hypotension may occur.

Alcohol exhibits additive vasodilating effects with isosorbide dinitrate.

Alcohol exhibits additive vasodilating effects with isosorbide mononitrate, potentially causing additive hypotensive effects.

Concomitant use may cause CNS depression and cognitive/neuropsychiatric adverse reactions. Should be used with extreme caution.

Concomitant use may enhance CNS depression and cognitive/neuropsychiatric effects; use with caution.

Concomitant use may result in accelerated release of levomilnacipran. Avoid concomitant use.

Alcohol potentiates the effect of metformin on lactate metabolism, increasing lactic acidosis risk. Patients should avoid excessive alcohol intake.

Lofexidine may potentiate CNS depressant effects of alcohol.

Lofexidine may potentiate CNS depressant effects of alcohol.

Substantial consumption (5+ units) combined with OPSYNVI increases potential for orthostatic signs and symptoms including dizziness and headache.

Alcohol induces renal losses of magnesium.

Alcohol induces renal losses of magnesium, potentially leading to hypomagnesemia.

Coadministration may result in increased CNS depression when used concurrently with meclizine.

Coadministration may result in increased CNS depression.

Sedative effects of metaxalone and alcohol may be additive. Exercise caution and monitor for respiratory depression and sedation.

Potentiates metformin's effect on lactate metabolism, increasing lactic acidosis risk with excessive intake.

Potentiates the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake.

Potentiates metformin's effect on lactate metabolism, increasing lactic acidosis risk with excessive intake.

Potentiates metformin's effect on lactate metabolism, increasing risk for lactic acidosis with excessive intake.

Methocarbamol may potentiate the effects of alcohol and CNS depressants.

Methohexital may influence the metabolism of ethyl alcohol.

Hypotensive effects may be potentiated by volume contraction associated with metolazone therapy.

Interferes with extended-release properties of metoprolol succinate, causing faster release and increasing risk of adverse events.

Concurrent use with metyrosine can increase sedative effects of alcohol.

Concomitant use increases impairment of cognitive and motor skills. Avoid concomitant use.

Additive CNS depressant effects; increases positive subjective mood effects. Caution must be used when administering nabilone in combination with CNS depressants.

May increase blood-glucose-lowering effect and susceptibility to hypoglycemia. Dose reductions and increased glucose monitoring may be required.

Nefazodone did not potentiate cognitive and psychomotor effects in normal subjects, but concomitant use not advised in depressed patients.

Concomitant alcohol may increase side effects of flushing and pruritus and should be avoided at time of drug ingestion.

The response to alcohol may be exaggerated in patients taking nortriptyline hydrochloride.

Co-administration potentiates orthostatic hypotension observed with olanzapine.

May potentiate sedation and orthostatic hypotension.

Concomitant use may potentiate orthostatic hypotension observed with olanzapine. LYBALVI should be used with caution.

Co-administration with olanzapine potentiates orthostatic hypotension.

Concurrent use with alcohol may cause somnolence and impairment of central nervous system performance.

CNS effects; use caution in combination and avoid alcohol.

Concomitant use may modulate CNS effects of paliperidone palmitate. Use with caution.

Concomitant use may result in an adverse drug reaction.

Concomitant use may potentiate CNS depression including dizziness and cognitive adverse reactions.

Concomitant use may potentiate CNS depression such as dizziness or cognitive adverse reactions. Caution against excessive intake advised.

Concomitant use may result in adverse drug reaction.

May increase phenytoin serum levels; monitoring of phenytoin levels recommended.

May increase phenytoin serum levels; monitoring of phenytoin levels recommended.

Pimozide may potentiate CNS depressant effects of alcohol.

Potentiates metformin effect on lactate metabolism, increasing lactic acidosis risk. Patients should be warned against excessive alcohol intake.

Additive effects on cognitive and gross motor functioning observed when co-administered with pregabalin.

Additive effects on cognitive and gross motor functioning when co-administered with pregabalin.

Promethazine may increase, prolong, or intensify the sedative action of alcohol; avoid or use reduced dosage.

Promethazine may increase, prolong, or intensify sedative action; agents should be avoided or administered in reduced dosage.

Hepatic enzyme inducer that decreases blood levels of propranolol by increasing hepatic metabolism.

Protriptyline may enhance the response to alcohol.

Produces additive CNS depressant effects. Downward dose adjustment may be necessary.

Caution should be used due to additive CNS effects when alcohol is administered with risperidone.

Potentiates effect of metformin on lactate metabolism. Excessive alcohol intake should be avoided.

Avoid alcoholic beverages during SOLOSEC therapy and for 2 days after treatment. Concomitant use may cause nausea, vomiting, diarrhea, abdominal pain, dizziness, and headache.

Co-administration of sildenafil 50 mg with alcohol studied; interaction mentioned but full severity details cut off in provided text.

Potentiation of orthostatic hypotension may occur.

Potentiation of orthostatic hypotension may occur.

Concomitant use of DIACOMIT with alcohol may increase the risk of sedation and somnolence.

Additive psychomotor impairment demonstrated when co-administered with suvorexant.

Concomitant use may have additive effects and worsen sedation and somnolence.

Alcohol concomitantly with thalidomide may cause additive sedative effect and should be avoided. Alcohol also causes peripheral neuropathy.

A single large dose of alcohol decreases theophylline clearance for up to 24 hours, resulting in approximately 30% increase in serum concentration.

Alcoholic beverages should be avoided during tinidazole therapy and for 3 days after because abdominal cramps, nausea, vomiting, headaches, and flushing may occur.

Alcohol increases the release rate of tiopronin from VENXXIVA formulation; risk of adverse events is unknown. Avoid alcohol consumption 2 hours before and 3 hours after taking VENXXIVA.

Trazodone may enhance effects of alcohol and other CNS depressants.

Concurrent use may cause increased sedative effects and additive CNS depression with trihexyphenidyl.

Alcohol may increase CNS depressant effects and cause drowsiness. Avoid concomitant use.

Concomitant use of alcoholic beverages may be associated with exaggerated effects of trimipramine.

Concomitant use of alcoholic beverages may be associated with exaggerated effects of trimipramine maleate.

Alcohol increases the release rate of Venlafaxine Extended-Release Tablets. Concomitant use should be avoided.

CNS-active substance with unsystematically evaluated risk when combined with venlafaxine. Caution advised.

Risk of concomitant use has not been systematically evaluated. Caution is advised.

Verapamil inhibits alcohol elimination, resulting in elevated ethanol levels.

Compounds that quench active oxygen species or scavenge radicals would be expected to decrease VISUDYNE activity.

Zaleplon potentiated CNS-impairing effects of ethanol on balance testing, reaction time, and divided attention for up to 2.5 hours. Pharmacodynamic interaction without altered ethanol pharmacokinetics.

Concomitant use may increase CNS depression and cognitive/neuropsychiatric adverse events. Use with caution.

Concomitant use may increase impairment of psychomotor performance or CNS depressant effects. Consider dosage reduction if use is unavoidable.

Acamprosate does not affect the pharmacokinetics of alcohol, and alcohol does not affect acamprosate pharmacokinetics.

Acamprosate does not affect the pharmacokinetics of alcohol, and alcohol does not affect the pharmacokinetics of acamprosate.

No disulfiram-like reactions were reported in a study of 22 healthy volunteers administered cefotaxime and ethanol.

Sildenafil 50 mg given with alcohol did not potentiate the hypotensive effect of alcohol in health subjects at mean maximum blood alcohol levels of 0.08%.

Alcohol consumed 30 minutes prior to sumatriptan ingestion had no effect on the pharmacokinetics of sumatriptan.

Vardenafil did not potentiate the hypotensive effects of alcohol during the 4-hour observation period in healthy volunteers.